{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:46:19Z","timestamp":1780710379960,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772991"],"award-info":[{"award-number":["81772991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572466"],"award-info":[{"award-number":["81572466"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372564"],"award-info":[{"award-number":["81372564"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772884"],"award-info":[{"award-number":["81772884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous findings have indicated that the tumor, nodes, and metastases (TNM) staging system is not sufficient to accurately predict survival outcomes in patients with non-small lung carcinoma (NSCLC). Thus, this study\u00a0aims to identify a long non-coding RNA (lncRNA) signature for predicting survival in patients with NSCLC and to provide additional prognostic information to TNM staging\u00a0system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with NSCLC were recruited from a hospital and divided into a discovery cohort (n\u2009=\u2009194) and validation cohort (n\u2009=\u2009172), and detected using a custom lncRNA microarray. Another 73\u00a0NSCLC\u00a0cases obtained from a different hospital (an independent validation cohort) were examined with qRT-PCR. Differentially expressed lncRNAs were determined with the Significance Analysis of Microarrays program, from which lncRNAs associated with survival were identified using Cox regression\u00a0in the discovery cohort. These prognostic lncRNAs were employed to construct a prognostic signature with a risk-score method. Then, the utility of the prognostic signature was confirmed using the validation cohort and the independent cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the discovery cohort, we identified 305 lncRNAs that were differentially expressed between the NSCLC tissues and matched, adjacent normal lung tissues, of which 15 are associated with survival; a 4-lncRNA prognostic signature was identified from the 15 survival lncRNAs, which was significantly correlated with survivals of NSCLC patients. This signature was further validated in the validation cohort and independent validation\u00a0cohort. Moreover, multivariate Cox analysis demonstrates that the 4-lncRNA signature is an independent survival predictor. Then we established a new risk-score model by combining 4-lncRNA signature and TNM staging\u00a0stage. The receiver operating characteristics (ROC) curve indicates that the prognostic value of the combined model is significantly higher than that of the TNM stage alone, in all the cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we identified a 4-lncRNA signature that may be\u00a0a powerful prognosis biomarker and can provide additional survival information to the TNM staging system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-020-02485-8","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T09:04:32Z","timestamp":1597914272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China"],"prefix":"10.1186","volume":"18","author":[{"given":"Rui-Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ran","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Juan","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-4376","authenticated-orcid":false,"given":"Hui-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2485_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2485_CR2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","volume":"11","author":"VW Rusch","year":"2016","unstructured":"Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Salle F, McCaughan BC, Nakano T, et al. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol. 2016;11:2112\u20139.","journal-title":"J Thorac Oncol"},{"key":"2485_CR3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"2485_CR4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023\u201375.","journal-title":"Lancet"},{"key":"2485_CR5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1148\/rg.2018170081","volume":"38","author":"BW Carter","year":"2018","unstructured":"Carter BW, Lichtenberger JP 3rd, Benveniste MK, de Groot PM, Wu CC, Erasmus JJ, Truong MT. Revisions to the TNM staging of lung cancer: rationale, significance, and clinical application. Radiographics. 2018;38:374\u201391.","journal-title":"Radiographics"},{"key":"2485_CR6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","volume":"377","author":"M Reck","year":"2017","unstructured":"Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377:849\u201361.","journal-title":"N Engl J Med"},{"key":"2485_CR7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.gpb.2016.03.007","volume":"14","author":"MM Wei","year":"2016","unstructured":"Wei MM, Zhou GB. Long non-coding RNAs and their roles in non-small-cell lung cancer. Genom Proteom Bioinform. 2016;14:280\u20138.","journal-title":"Genom Proteom Bioinform"},{"key":"2485_CR8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s40880-015-0028-4","volume":"34","author":"B Fang","year":"2015","unstructured":"Fang B, Mehran RJ, Heymach JV, Swisher SG. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer. 2015;34:295\u2013309.","journal-title":"Chin J Cancer"},{"key":"2485_CR9","doi-asserted-by":"crossref","first-page":"djw200","DOI":"10.1093\/jnci\/djw200","volume":"109","author":"S Shukla","year":"2017","unstructured":"Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst. 2017;109:djw200.","journal-title":"J Natl Cancer Inst"},{"key":"2485_CR10","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.18632\/aging.101550","volume":"10","author":"T Lin","year":"2018","unstructured":"Lin T, Fu Y, Zhang X, Gu J, Ma X, Miao R, Xiang X, Niu W, Qu K, Liu C, Wu Q. A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer. Aging. 2018;10:2356\u201366.","journal-title":"Aging"},{"key":"2485_CR11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(16)31340-X","volume":"388","author":"CT Hiley","year":"2016","unstructured":"Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, Swanton C. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388:1002\u201311.","journal-title":"Lancet"},{"key":"2485_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5603\/ARM.2019.0019","volume":"87","author":"BA Lochowska","year":"2019","unstructured":"Lochowska BA, Nowak D, Bialasiewicz P. Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma. Adv Respir Med. 2019;87:118\u201322.","journal-title":"Adv Respir Med"},{"key":"2485_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa060096","volume":"356","author":"HY Chen","year":"2007","unstructured":"Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11\u201320.","journal-title":"N Engl J Med"},{"key":"2485_CR14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/JTO.0000000000000470","volume":"10","author":"H Yu","year":"2015","unstructured":"Yu H, Xu Q, Liu F, Ye X, Wang J, Meng X. Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. J Thorac Oncol. 2015;10:645\u201354.","journal-title":"J Thorac Oncol"},{"key":"2485_CR15","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1038\/onc.2011.621","volume":"31","author":"R Spizzo","year":"2012","unstructured":"Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577\u201387.","journal-title":"Oncogene"},{"key":"2485_CR16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg.2015.17","volume":"17","author":"E Khurana","year":"2016","unstructured":"Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M. Role of non-coding sequence variants in cancer. Nat Rev Genet. 2016;17:93\u2013108.","journal-title":"Nat Rev Genet"},{"key":"2485_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrg2521","volume":"10","author":"TR Mercer","year":"2009","unstructured":"Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155\u20139.","journal-title":"Nat Rev Genet"},{"key":"2485_CR18","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1007\/s00018-013-1423-0","volume":"70","author":"M Kitagawa","year":"2013","unstructured":"Kitagawa M, Kitagawa K, Kotake Y, Niida H, Ohhata T. Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci. 2013;70:4785\u201394.","journal-title":"Cell Mol Life Sci"},{"key":"2485_CR19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.1231776","volume":"338","author":"JT Lee","year":"2012","unstructured":"Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338:1435\u20139.","journal-title":"Science"},{"key":"2485_CR20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452\u201363.","journal-title":"Cancer Cell"},{"key":"2485_CR21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","volume":"73","author":"T Gutschner","year":"2013","unstructured":"Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180\u20139.","journal-title":"Cancer Res"},{"key":"2485_CR22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1097\/JTO.0b013e3182307eac","volume":"6","author":"LH Schmidt","year":"2011","unstructured":"Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984\u201392.","journal-title":"J Thorac Oncol"},{"key":"2485_CR23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/JTO.0000000000000243","volume":"9","author":"LH Schmidt","year":"2014","unstructured":"Schmidt LH, Gorlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Huge A, et al. Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol. 2014;9:1294\u2013304.","journal-title":"J Thorac Oncol"},{"key":"2485_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3727\/096504017X15009404458675","volume":"26","author":"S Li","year":"2018","unstructured":"Li S, Yang J, Xia Y, Fan Q, Yang KP. Long noncoding RNA NEAT1 promotes proliferation and invasion via targeting miR-181a-5p in non-small cell lung cancer. Oncol Res. 2018;26:289\u201396.","journal-title":"Oncol Res"},{"key":"2485_CR25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.biopha.2018.04.053","volume":"103","author":"L Qi","year":"2018","unstructured":"Qi L, Liu F, Zhang F, Zhang S, Lv L, Bi Y, Yu Y. lncRNA NEAT1 competes against let-7a to contribute to non-small cell lung cancer proliferation and metastasis. Biomed Pharmacother. 2018;103:1507\u201315.","journal-title":"Biomed Pharmacother"},{"key":"2485_CR26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1101\/gr.2885205","volume":"15","author":"HY Wang","year":"2005","unstructured":"Wang HY, Luo M, Tereshchenko IV, Frikker DM, Cui X, Li JY, Hu G, Chu Y, Azaro MA, Lin Y, et al. A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res. 2005;15:276\u201383.","journal-title":"Genome Res"},{"key":"2485_CR27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1261\/rna.234507","volume":"13","author":"H Wang","year":"2007","unstructured":"Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA. 2007;13:151\u20139.","journal-title":"RNA"},{"key":"2485_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2007.12.008","volume":"13","author":"SL Yu","year":"2008","unstructured":"Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48\u201357.","journal-title":"Cancer Cell"},{"key":"2485_CR29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(12)70102-X","volume":"13","author":"N Liu","year":"2012","unstructured":"Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633\u201341.","journal-title":"Lancet Oncol"},{"key":"2485_CR30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2009.24.9342","volume":"28","author":"Z Hu","year":"2010","unstructured":"Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721\u20136.","journal-title":"J Clin Oncol"},{"key":"2485_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12967-015-0556-3","volume":"13","author":"M Zhou","year":"2015","unstructured":"Zhou M, Guo M, He D, Wang X, Cui Y, Yang H, Hao D, Sun J. A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer. J Transl Med. 2015;13:231.","journal-title":"J Transl Med"},{"key":"2485_CR32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fonc.2019.00693","volume":"9","author":"R He","year":"2019","unstructured":"He R, Zuo S. A robust 8-gene prognostic signature for early-stage non-small cell lung cancer. Front Oncol. 2019;9:693.","journal-title":"Front Oncol"},{"key":"2485_CR33","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.7314\/APJCP.2015.16.7.2851","volume":"16","author":"LJ Pan","year":"2015","unstructured":"Pan LJ, Zhong TF, Tang RX, Li P, Dang YW, Huang SN, Chen G. Upregulation and clinicopathological significance of long non-coding NEAT1 RNA in NSCLC tissues. Asian Pac J Cancer Prev. 2015;16:2851\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2485_CR34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.33594\/000000026","volume":"52","author":"X Kong","year":"2019","unstructured":"Kong X, Zhao Y, Li X, Tao Z, Hou M, Ma H. Overexpression of HIF-2alpha-dependent NEAT1 promotes the progression of non-small cell lung cancer through miR-101-3p\/SOX9\/Wnt\/beta-catenin signal pathway. Cell Physiol Biochem. 2019;52:368\u201381.","journal-title":"Cell Physiol Biochem"},{"key":"2485_CR35","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.2017.72.4401","volume":"35","author":"MG Kris","year":"2017","unstructured":"Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology\/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017;35:2960\u201374.","journal-title":"J Clin Oncol"},{"key":"2485_CR36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16:341\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"2485_CR37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","volume":"28","author":"MG Best","year":"2015","unstructured":"Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28:666\u201376.","journal-title":"Cancer Cell"},{"key":"2485_CR38","doi-asserted-by":"crossref","first-page":"14924","DOI":"10.1073\/pnas.1520329112","volume":"112","author":"P Gasparini","year":"2015","unstructured":"Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Ali G, D\u2019Incecco A, Minuti G, Chella A, et al. microRNA classifiers are powerful diagnostic\/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci USA. 2015;112:14924\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2485_CR39","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301.","journal-title":"N Engl J Med"},{"key":"2485_CR40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"2485_CR41","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454\u201366.","journal-title":"Lancet Oncol"},{"key":"2485_CR42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2013.09.041","volume":"155","author":"HS Kim","year":"2013","unstructured":"Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013;155:552\u201366.","journal-title":"Cell"},{"key":"2485_CR43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764\u201374.","journal-title":"JAMA"},{"key":"2485_CR44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2004.07.040","volume":"47","author":"TA Hensing","year":"2005","unstructured":"Hensing TA, Schell MJ, Lee JH, Socinski MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005;47:253\u20139.","journal-title":"Lung Cancer"},{"key":"2485_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2017.04.009","volume":"109","author":"L Zhang","year":"2017","unstructured":"Zhang L, Li S, Choi YL, Lee J, Gong Z, Liu X, Pei Y, Jiang A, Ye M, Mao M, et al. Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-seq. Lung Cancer. 2017;109:21\u20137.","journal-title":"Lung Cancer"},{"key":"2485_CR46","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","volume":"321","author":"G Singal","year":"2019","unstructured":"Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA. 2019;321:1391\u20139.","journal-title":"JAMA"},{"key":"2485_CR47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"2485_CR48","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2012.48.5516","volume":"31","author":"J Sandoval","year":"2013","unstructured":"Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 2013;31:4140\u20137.","journal-title":"J Clin Oncol"},{"key":"2485_CR49","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/1061186X.2019.1585437","volume":"27","author":"B Li","year":"2019","unstructured":"Li B, Gu W, Zhu X. NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt\/mTOR signalling pathway. J Drug Target. 2019;27:1061\u20137.","journal-title":"J Drug Target"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02485-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02485-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02485-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T19:30:47Z","timestamp":1629401447000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02485-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2485"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02485-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-24087\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-24087\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Research Ethics Committee of Sun Yat-Sen University Cancer Center. The research was conducted according to all ethical standards, and written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish was obtained from all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}